Pöördumine

Saatja: <[email protected]> Saadetud: 28.02.2023 16:30 Teema: WHO: C.L.4.2023 (INN proposed list 128 - COVID-19 special edition - addendum 2) Manused: C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (Arabic).pdf; C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (Chinese).pdf; C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (English).pdf; C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (French).pdf; C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (Russian).pdf; C.L.4.2023 INN Proposed List 128 - COVID-19 edition - Addendum 2 (Spanish).pdf Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.4.2023 regarding the list 128 of proposed international nonproprietary names, COVID-19 special edition, addendum 2. Best regards, Department of Governing Bodies World Health Organization ***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY*** 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.4.2023 The World Health Organization presents its compliments and has the honour to transmit, in accordance with Article 3 of the “Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances”,1 the following lists of proposed international nonproprietary names (prop. INN) which has been published by the World Health Organization in WHO Drug Information, Vol. 36, No. 4, 2022. It would be appreciated if this communication could be forwarded to the appropriate patent and trade-mark office and to any other organization dealing with the introduction of nonproprietary names for pharmaceutical substances. Any comments that may be made, or notifications of a conflict between proposed names and existing proprietary rights, should be addressed to the INN Programme, World Health Organization, 1211 Geneva 27, within four months following the publication of the above-mentioned journal, for: - p.INN list 128 from p. 929 to 1128 (deadline for objecting and commenting is 19 May 2023). - p.INN list 128 – COVID-19 (special edition ADDENDUM 2) p. 1134 to 1145 (deadline for objecting and commenting is 19 May 2023). - p.INN list 128 – COVID-19 (special edition) p. 1129 to 1130 (This part has already been published, deadline for objecting and commenting was 22 August 2022). - p.INN list 128 – COVID-19 (special edition ADDENDUM 1) p. 1131 to 1133 (This part has already been published, deadline for objecting and commenting was 29 September 2022. The World Health Organization furthermore has the honour to transmit, in accordance with the “International Nonproprietary Names for Variant COVID-19 Vaccine Active Substances” document available on WHO website: https://www.who.int/publications/i/item/inn-21-520 (INN Working Document 21.520 April 2021), the following list of proposed international nonproprietary names (prop. INN) which has been published by the World Health Organization on the WHO website at https://www.who.int/publications/i/item/who-drug-information-volume-36-no-4. The selection of international nonproprietary names by the World Health Organization for use in all Member States presents many difficulties. It would therefore be appreciated if this were borne in mind when it is contemplated to exercise the right to raise objections. Furthermore, the World Health Organization would be grateful if, in the interest of public health and pursuant to the procedure referred to in the first paragraph of this communication, the lists of names could be granted protection in Member States during the period they are under consideration by the World Health Organization as international nonproprietary names. GENEVA, 24 February 2023 1 Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by resolution EB43.R9, Off. Rec. Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board, 115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2.